Latest News

Open Briefing Interview with MD Andrew McLellan – Oct 2019

12 October 2019

In this Open Briefing®, Andrew discusses: Significant increase in cash receipts for the quarter ended 30 September 2019 Outlook for further growth in chip volumes and sales over the coming quarters Production of prototype consumables for potential new OEM partner Expanding production and supply chain capacity to allow for tens of millions of chips per…

Discover More >

June 2019 Quarterly Cash Flow Report

24 July 2019

Download the official ASX announcement HERE: https://www.asx.com.au/asxpdf/20190724/pdf/446v0xxd73w4sr.pdf Bluechiip Limited (Bluechiip or the Company) (ASX: BCT) today released its quarterly cash flow report for the quarter ended 30 June 2019. ACTIVITIES REPORT FOR THE QUARTER ENDED 30 JUNE 2019 Business highlights A record quarter with net sales revenue of $517k (unaudited) from the delivery of readers,…

Discover More >

Open Briefing interview with MD Andrew McLellan – Jul 2019

24 July 2019

You can download the original announcement HERE: https://www.asx.com.au/asxpdf/20190724/pdf/446v120vjdzp8z.pdf In this Open Briefing®, Andrew discusses: Quarterly cash results for quarter ended 30 June2019 Growth in the installed reader base, enabling growth in use of Bluechiip technology and consumables Expected step up increase in cash receipts in the coming quarters and ongoing sales growth Additional OEM proposals…

Discover More >

Bluechiip Sample Management System featured at ISBER Shanghai 2019

12 June 2019

This May at the ISBER annual meeting, the team lead by Cristina Villena from the Pulmonary Biobank Platform (PBP) in Son Espases Hospital, Spain presented a poster about enhancing productivity in biobanking operations. The Bluechiip Sample Management System (under the “MEMS” technology denomination) showed a significant increase in productivity over traditional 1D labels and 2D…

Discover More >

Open Briefing interview with MD Andrew McLellan – Mar 2019

04 March 2019

In this Open Briefing®, Andrew discusses: • Four new OEM proposals under consideration • Growing market enquiries and successful trade shows including ISBER and SLAS • Six months trading results, period ended 31 December 2018 • Changing revenue mix to ongoing consumables sales • Increasing production and delivery under US$11.9m Labcon contract Open Briefing interview…

Discover More >